| Product Code: ETC13331789 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
North America Oncology Anti-Cancer Drugs Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 North America Oncology Anti-Cancer Drugs Market Overview |
3.1 North America Regional Macro Economic Indicators |
3.2 North America Oncology Anti-Cancer Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 North America Oncology Anti-Cancer Drugs Market - Industry Life Cycle |
3.4 North America Oncology Anti-Cancer Drugs Market - Porter's Five Forces |
3.5 North America Oncology Anti-Cancer Drugs Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 North America Oncology Anti-Cancer Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.7 North America Oncology Anti-Cancer Drugs Market Revenues & Volume Share, By Cancer Type, 2021 & 2031F |
3.8 North America Oncology Anti-Cancer Drugs Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 North America Oncology Anti-Cancer Drugs Market Revenues & Volume Share, By Therapy Type, 2021 & 2031F |
3.10 North America Oncology Anti-Cancer Drugs Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 North America Oncology Anti-Cancer Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 North America Oncology Anti-Cancer Drugs Market Trends |
6 North America Oncology Anti-Cancer Drugs Market, 2021 - 2031 |
6.1 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Chemotherapy, 2021 - 2031 |
6.1.3 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Immunotherapy, 2021 - 2031 |
6.1.4 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Hormone Therapy, 2021 - 2031 |
6.1.5 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Targeted Therapy, 2020 - 2028 |
6.1.6 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Precision Medicine, 2020 - 2028 |
6.2 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Cancer Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Lung Cancer, 2021 - 2031 |
6.2.3 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Breast Cancer, 2021 - 2031 |
6.2.4 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Prostate Cancer, 2021 - 2031 |
6.2.5 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Colorectal Cancer, 2021 - 2031 |
6.2.6 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Leukemia, 2020 - 2028 |
6.3 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Oral, 2021 - 2031 |
6.3.3 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Intravenous, 2021 - 2031 |
6.3.4 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Subcutaneous, 2021 - 2031 |
6.3.5 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Topical, 2021 - 2031 |
6.3.6 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Intramuscular, 2021 - 2031 |
6.4 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Therapy Type, 2021 - 2031 |
6.4.2 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Targeted Therapy, 2021 - 2031 |
6.4.3 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Immunotherapy, 2021 - 2031 |
6.4.4 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Hormone Therapy, 2020 - 2028 |
6.4.5 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Chemotherapy, 2020 - 2028 |
6.4.6 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Combination Therapy, 2020 - 2028 |
6.5 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Distribution Channel, 2020 - 2028 |
6.5.1 Overview & Analysis |
6.5.2 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Hospital Pharmacies, 2020 - 2028 |
6.5.3 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Retail Pharmacies, 2020 - 2028 |
6.5.4 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Online Pharmacies, 2020 - 2028 |
6.5.5 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Specialty Pharmacies, 2020 - 2028 |
6.5.6 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Mail Order Pharmacies, 2020 - 2028 |
7 North America Oncology Anti-Cancer Drugs Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
7.2.1 United States (US) Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
7.2.2 Canada Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
7.2.3 Rest of North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Drug Class, 2021 - 2031 |
7.3 North America Oncology Anti-Cancer Drugs Market Revenues & Volume Share, By Cancer Type, 2021 & 2031F |
7.3.1 United States (US) Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Cancer Type, 2021 - 2031 |
7.3.2 Canada Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Cancer Type, 2021 - 2031 |
7.3.3 Rest of North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Cancer Type, 2021 - 2031 |
7.4 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.4.1 United States (US) Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.4.2 Canada Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.4.3 Rest of North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Route of Administration, 2021 - 2031 |
7.5 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Therapy Type, 2021 - 2031 |
7.5.1 United States (US) Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Therapy Type, 2021 - 2031 |
7.5.2 Canada Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Therapy Type, 2021 - 2031 |
7.5.3 Rest of North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Therapy Type, 2021 - 2031 |
7.6 North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
7.6.1 United States (US) Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
7.6.2 Canada Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
7.6.3 Rest of North America Oncology Anti-Cancer Drugs Market, Revenues & Volume, By Distribution Channel, 2021 - 2031 |
8 North America Oncology Anti-Cancer Drugs Market Key Performance Indicators |
9 North America Oncology Anti-Cancer Drugs Market - Export/Import By Countries Assessment |
10 North America Oncology Anti-Cancer Drugs Market - Opportunity Assessment |
10.1 North America Oncology Anti-Cancer Drugs Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 North America Oncology Anti-Cancer Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
10.3 North America Oncology Anti-Cancer Drugs Market Opportunity Assessment, By Cancer Type, 2021 & 2031F |
10.4 North America Oncology Anti-Cancer Drugs Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
10.5 North America Oncology Anti-Cancer Drugs Market Opportunity Assessment, By Therapy Type, 2021 & 2031F |
10.6 North America Oncology Anti-Cancer Drugs Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
11 North America Oncology Anti-Cancer Drugs Market - Competitive Landscape |
11.1 North America Oncology Anti-Cancer Drugs Market Revenue Share, By Companies, 2022 |
11.2 North America Oncology Anti-Cancer Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here